NCT05529342
Long-term Follow-up of Study Participant Treated With Lentiviral-Based Genetically Modified Autologous Cell Product ,AGT103-T
Enrolling by Invitation
Not specifiedAges 18+ObservationalAmerican Gene Technologies International Inc.
~7 participants
Updated 2022-12-02 on ClinicalTrials.gov
What's tested:Gene modified therapy
At a glance
Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Assess the incidence of delayed adverse events (AE) to gene therapy
Measured over 1year to 15years post infusion
Conditions
Where it's being run
2 sites across 1 statesDistrict of Columbia2
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Assess the incidence of delayed adverse events (AE) to gene therapy1year to 15years post infusion
The presence of malignancies, incidence or exacerbation of pre-existing neurologic disorder, new incidence or exacerbation of a prior rheumatologic or other autoimmune disorder, the new incidence of a hematologic disorder post infusion with AGT103T